Table 3.
Disease and treatment characteristics from first to fourth treatment line.
| First Line | Second Line | Third Line | Fourth Line | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Patients N. (%) | 130 (100) | 130 (100) | 130 (100) | 88 (68) | |||||
| Secretory disease | normo-secretory | 130 | 106 (82) | 130 | 87 (67) | 130 | 82 (63) | 88 | 57 (65) |
| oligo-secretory/ micromolecular |
24 (18) | 43 (33) | 49 (37) | 31 (35) | |||||
| Cytogenetic risk | standard | 55 | 46 (84) | 12 | 10 (83) | 15 | 10 (67) | 8 | 5 (62) |
| high | 11 (16) | 2 (17) | 5 (33) | 3 (38) | |||||
| Baseline LDH | normal | 99 | 84 (85) | 114 | 91 (80) | 113 | 92 (81) | 78 | 67 (86) |
| increased | 15 (15) | 23 (20) | 21 (19) | 11 (14) | |||||
| ECOG | <3 | 130 | 104 | 130 | 103 | 130 | 101 | 88 | 53 |
| ≥3 | 26 | 27 | 29 | 35 | |||||
| Treatement type | continuous | 130 | 48 (37) | 130 | 72 (55) | 130 | 91 (70) | 88 | 58 (66) |
| fixed duration | 82 (63) | 58 (45) | 39 (30) | 30 (34) | |||||
| Treatement type | triplets | 50 | 23 (46) | 89 | 26 (29) | 99 | 23 (23) | 58 | 19 (33) |
| doublets | 27 (54) | 63 (71) | 76 (77) | 39 (67) | |||||
| Response | CR | 130 | 31 (24) | 130 | 22 (17) | 130 | 14 (11) | 88 | 6 (7) |
| VGPR | 36 (28) | 15 (12) | 12 (9) | 10 (11) | |||||
| PR | 42 (32) | 61 (47) | 55 (42) | 32 (36) | |||||
| <PR | 21 (16) | 32 (24) | 49 (38) | 40 (46) | |||||
| Relapse type | clinical | 130 | 90 (69) | 130 | 96 (74) | 109 | 88 (81) | 74 | 56 (76) |
| biochemical | 40 (31) | 34 (26) | 21 (19) | 18 (24) | |||||
| Extramedullary disease | no | 130 | 126 (97) | 130 | 126 (97) | 130 | 126 (97) | 88 | 86 (98) |
| yes | 4 (3) | 4 (3) | 4 (3) | 2 (2) | |||||
| Lenalidomide refcractory | no | 130 | N.E. | 130 | 111 (85) | 130 | 54 (42) | 88 | 23 (26) |
| yes | N.E. | 19 (15) | 76 (58) | 65 (74) | |||||
Abbreviations: N.E.—not evaluable; CR- complete response; VGPR—very good partial response; PR—partial response.